{"title":"First person – Ateequllah Hayat","authors":"","doi":"10.1242/dmm.050100","DOIUrl":null,"url":null,"abstract":"\n First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping researchers promote themselves alongside their papers. Ateequllah Hayat is first author on ‘ Low HER2 expression in normal breast epithelium enables dedifferentiation and malignant transformation via chromatin opening’, published in DMM. Ateequllah conducted the research described in this article while a PhD student in Gabriella Ficz's lab at Queen Mary University of London, London, UK, and is now a lecturer in drug development at St George's, University of London, London, UK, investigating transcriptomic/epigenomic changes in cancer resistance.","PeriodicalId":141347,"journal":{"name":"Disease Models & Mechanisms","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Disease Models & Mechanisms","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1242/dmm.050100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping researchers promote themselves alongside their papers. Ateequllah Hayat is first author on ‘ Low HER2 expression in normal breast epithelium enables dedifferentiation and malignant transformation via chromatin opening’, published in DMM. Ateequllah conducted the research described in this article while a PhD student in Gabriella Ficz's lab at Queen Mary University of London, London, UK, and is now a lecturer in drug development at St George's, University of London, London, UK, investigating transcriptomic/epigenomic changes in cancer resistance.